Month: <span>August 2019</span>

Philips Collaborates with LindaCare for the Remote Monitoring of Patients

Shots: The collaboration combines LindaCare’s innovative OnePulse cloud-based solution with Philips IntelliSpace Cardiovascular informatics platform, allowing clinicians to access data of patients with cardiac implantable electronic devices (CIEDs) remotely Lindacare’s OnePulse platform aggregates data from cardiac electronic implantable devices and makes it available on a single platform providing workflow automation and seamless integration with electronic […]Read More

Janssen Extends its Research and Licensing Agreement with SVI to

Shots: SVI to receive development milestones, royalties and option exercise fee. Janssen to exercise its option and will be responsible for all development of small molecule modulators of microglial function and inflammation for Alzheimer’s disease In Aug’2017, Janssen collaborated with SVI to develop & commercialize small molecule modulators of microglial function and inflammation focusing the […]Read More

Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS I

Shots: The P-III ASCLEPIOS I and II (NCT02792218 and NCT02792231) studies involve assessing of Ofatumumab (20mg, SC, monthly) vs Aubagio (teriflunomide, 14mg, qd) in 1,882 patients with MS aged 18-55yrs. across 37 countries The P-III ASCLEPIOS I and II studies resulted in meetings their 1EPs & 2EPs i.e, @30mos. reduction in annualized relapse rate evaluated […]Read More

Roche Reports Launch of First CDx VENTANA PD-L1 (SP142) Assay

Shots: The launch of VENTANA PD-L1 (SP142) follows the US FDA’s approval in Mar’2019, as the first CDx assay involved in identifying triple-negative breast cancer (TNBC) patients associated with 3 proteins estrogen receptor, progesterone receptor and HER2/neu eligible for treatment with Tecentriq combination The assay is developed for the enhancement of visual contrast of tumor-infiltrating […]Read More

AstraZeneca Reports Results of Anifrolumab in P-III TULIP 2 Study

Shots: The P-III TULIP 2 study involves assessing of anifrolumab (300mg, FD, IV) vs PBO in 373 patients in ratio (1:1) for adults with moderate-to-severe SLE and has demonstrated meeting its 1EPs with reduction in disease activity which was assessed using BICLA @52 wks. and the safety profile was also consistent with previous trials  The […]Read More